中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2015年
11期
10-11
,共2页
厄贝沙坦%糖尿病%肾病%同型半胱氨酸%颈动脉内膜
阨貝沙坦%糖尿病%腎病%同型半胱氨痠%頸動脈內膜
액패사탄%당뇨병%신병%동형반광안산%경동맥내막
irbesartan%diabetes%nephropathy%homocysteine%carotid arterial intima
目的：观察厄贝沙坦对早期糖尿病肾病患者临床血生化指标、血浆同型半胱氨酸( Hcy )及颈动脉内膜中层厚度( IMT )的影响。方法将2011年至2013年收治的100例早期糖尿病肾病患者，按住院号随机分为观察组和对照组，各50例。对照组给予常规降血糖治疗，观察组在常规治疗基础上联合厄贝沙坦治疗。结果对照组治疗前后三酰甘油（TG）、总胆固醇( TC )、高密度脂蛋白胆固醇( HDL－C )、空腹血糖( FBG )、胰岛素抵抗指数( HOMA－IR )差异无统计学意义（ P>0.05），观察组治疗前后血脂、血糖、HOMA－IR和治疗前比较差异均有统计学意义（ P<0.05），且TG，TC，低密度脂蛋白胆固醇( LDL－C )水平较对照组下降更明显（ P<0.05）；对照组治疗前后24 h尿微量蛋白、Hcy及IMT差异无统计学意义（ P>0.05），观察组治疗前后均显著降低（ P<0.05），同对照组治疗后比较显著降低（ P<0.05）。结论厄贝沙坦治疗早期糖尿病肾病可改善血脂水平，降低尿微量蛋白、Hcy水平和颈动脉IMT厚度，在一定程度上起到了保护肾脏的作用。
目的：觀察阨貝沙坦對早期糖尿病腎病患者臨床血生化指標、血漿同型半胱氨痠( Hcy )及頸動脈內膜中層厚度( IMT )的影響。方法將2011年至2013年收治的100例早期糖尿病腎病患者，按住院號隨機分為觀察組和對照組，各50例。對照組給予常規降血糖治療，觀察組在常規治療基礎上聯閤阨貝沙坦治療。結果對照組治療前後三酰甘油（TG）、總膽固醇( TC )、高密度脂蛋白膽固醇( HDL－C )、空腹血糖( FBG )、胰島素牴抗指數( HOMA－IR )差異無統計學意義（ P>0.05），觀察組治療前後血脂、血糖、HOMA－IR和治療前比較差異均有統計學意義（ P<0.05），且TG，TC，低密度脂蛋白膽固醇( LDL－C )水平較對照組下降更明顯（ P<0.05）；對照組治療前後24 h尿微量蛋白、Hcy及IMT差異無統計學意義（ P>0.05），觀察組治療前後均顯著降低（ P<0.05），同對照組治療後比較顯著降低（ P<0.05）。結論阨貝沙坦治療早期糖尿病腎病可改善血脂水平，降低尿微量蛋白、Hcy水平和頸動脈IMT厚度，在一定程度上起到瞭保護腎髒的作用。
목적：관찰액패사탄대조기당뇨병신병환자림상혈생화지표、혈장동형반광안산( Hcy )급경동맥내막중층후도( IMT )적영향。방법장2011년지2013년수치적100례조기당뇨병신병환자，안주원호수궤분위관찰조화대조조，각50례。대조조급여상규강혈당치료，관찰조재상규치료기출상연합액패사탄치료。결과대조조치료전후삼선감유（TG）、총담고순( TC )、고밀도지단백담고순( HDL－C )、공복혈당( FBG )、이도소저항지수( HOMA－IR )차이무통계학의의（ P>0.05），관찰조치료전후혈지、혈당、HOMA－IR화치료전비교차이균유통계학의의（ P<0.05），차TG，TC，저밀도지단백담고순( LDL－C )수평교대조조하강경명현（ P<0.05）；대조조치료전후24 h뇨미량단백、Hcy급IMT차이무통계학의의（ P>0.05），관찰조치료전후균현저강저（ P<0.05），동대조조치료후비교현저강저（ P<0.05）。결론액패사탄치료조기당뇨병신병가개선혈지수평，강저뇨미량단백、Hcy수평화경동맥IMT후도，재일정정도상기도료보호신장적작용。
Objective To investigate the influence of irbeartan on clinical blood biochemical indicators, plasma homocysteine ( Hcy ) , carotid intima-media thickness ( IMT ) in the patients with early diabetic nephropathy. Methods 100 cases of early diabetic nephropathy in our hospital during 2011-2013 were randomly divided into the observation group and the control group according to the admission num-ber, 50 cases in each group. The control group was treated with routine hypoglycemic therapy, while on the basis of the conventional treatment the observation group was given irbesartan. Results TG, TC, HDL-c, FPG and HOMA-IR after treatment in the control group had no statistically significant differences compared with before treatment ( P > 0. 05 ) , but the blood lipids, blood glucose and HOMA-IR in the observation group had statistically significant differences between before and after treatment of the observation group had compared with before treatment ( P < 0. 05 ) , moreover the decrease of the TG, TC and LDL-c levels was more significant than that of the control group ( P < 0. 05 );24 h urine microprotein, Hcy, carotid arterial IMT of the control group had no statistically significant differences between before and after treatment ( P > 0. 05 ) , but 24 h urine microprotein, Hcy, carotid arterial IMT after treatment in the observation group were significantly decreased, the differences were statistically significant ( P < 0. 05 ) , which were significantly decreased compared with those after treatment in the control group ( P < 0. 05 ) . Conclusion Irbesartan can improve the blood lipid levels, reduces urine microprotein level, Hcy level and carotid arterial IMT in the treatment of early diabetic nephropathy and plays a role for protect-ing the renal function in a certain extent.
